The GeneSight Test

Fact Sheet

The GeneSight Psychotropic test from Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, analyzes how a patient's genes may affect outcomes with certain medications commonly prescribed to treat depression, anxiety, ADHD, and other mental health conditions. The GeneSight test has been ordered by tens of thousands of physicians for more than two million patients. The GeneSight test provides healthcare providers with information about which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on a patient's unique genetic makeup.

The GeneSight Test

- The GeneSight Psychotropic test identifies an individual's genetic variations that may impact how they metabolize or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD and other psychiatric conditions. The GeneSight report:
    - Shows whether there are gene-drug interactions for more than 60 FDA-approved medications including antidepressants, anxiolytics, hypnotics, antipsychotics, stimulants and non-stimulants; to see a list of medications, visit genesight.com/product
    - Details the individual's genotypes and phenotypes for five pharmacodynamic genes and nine pharmacokinetic genes; COMT has been included for informational purposes
- The GeneSight MTHFR test analyzes whether an individual has variation in MTHFR, which may limit their ability to create l-methylfolate

Helping with Trial-and-Error Depression Treatment

Trial-and-error prescribing for depression can cause frustration, wasted time, wasted money, and wasted medication for physicians and patients. According to a large study[1]:

- Less than 40% of study participants achieved remission with their first depression medication trial
- Only 31% of study participants achieved remission with their second medication trial
- Only 14% of study participants achieved remission with their third medication trial

From Sample Collection to Results in Days

The process is simple:

- A cheek swab is used to collect a sample of a patient's DNA
- Swabs are sent to our CLIA- and CAP-certified lab in prepaid FedEx envelopes
- About two days after we receive the sample, healthcare providers can access a patient's personalized report on their secure GeneSight portal

Backed by Multiple Clinical Studies

The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in more peer-reviewed publications than any other test in its category. In fact, it's the only neuropsychiatric pharmacogenomic test backed by such extensive research. While not all patients experienced improved outcomes, overall, the GeneSight Psychotropic test helped improve outcomes compared to treatment as usual in multiple clinical studies. To read more about our clinical studies, please visit genesight.com/for-clinicians/clinical-studies/.

Resources Available

Our team of PharmDs, PhDs, MDs, and genetic counselors is available to answer any questions physicians or patients may have about the GeneSight test. We can be reached at medinfo@myriad.com, or by phone at 855.891.9415. To order the GeneSight test, contact our sales team through genesight.com/take-the-next-step.

[1] Rush, et al, *The American Journal of Psychiatry*. 2006 Nov; 163(11):1905-17